Reports
Reports
The global emphysema treatment market size was valued at USD 4.4 billion in 2022, driven by increased implementation of strict regulatory policies by the governments. The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to reach a value of USD 7.3 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America accounts for a significant share in the industry owing to the growing cases of chronic obstructive pulmonary diseases (COPD) in the region and the availability of improved healthcare facilities. According to estimates, COPD is one of the leading causes of deaths in the United States. North America is followed by Europe. The availability of diagnostic services for respiratory illness is propelling the industry growth in the European region. Meanwhile, the growing presence of smoking population and the rising pollution levels in the Asia Pacific are expected to create new opportunities for the market expansion in the forecast period.
Emphysema, which is a type of chronic obstructive pulmonary disease (COPD), is a lung condition that leads to the shortness of breath due to the damage caused to the air sacs (alveoli) in the lungs. The patient suffering from emphysema can be treated by improving shortness of breath.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By treatment, the market is divided into:
Based on types of diseases, the industry can be segmented into:
Based on end use, the industry can be categorised into:
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increase in the number of tobacco smokers is driving the growth of the emphysema treatment industry. The growing prevalence of chronic lung disorders and the availability of advanced diagnostic facilities are resulting in the increased demand for treatment for emphysema. Other factors such as the sedentary lifestyle, growing urbanisation and industrialisation, and rising pollution levels are further propelling the industry growth. Over the forecast period, the growing R&D activities and the advancements in the medical sector are expected to drive the growth of the global emphysema treatment industry.
The report gives a detailed analysis of the following key players in the global emphysema treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Diagnosis |
|
Breakup by Type |
|
Breakup by Treatment Type |
|
Breakup by Route of Administration |
|
Breakup by Treatment Channel |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Emphysema Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Emphysema Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Emphysema Epidemiology (2016-2031)
5.3 Europe Emphysema Epidemiology (2016-2031)
5.4 Asia-Pacific Emphysema Epidemiology (2016-2031)
5.5 Latin America Emphysema Epidemiology (2016-2031)
5.6 Middle East & Africa Emphysema Epidemiology (2016-2031)
6 Global Emphysema Market Overview
6.1 Global Emphysema Market Historical Value (2016-2022)
6.2 Global Emphysema Market Forecast Value (2023-2031)
7 Global Emphysema Market Landscape
7.1 Global Emphysema Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Emphysema Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Emphysema Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Emphysema Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Emphysema Market Segmentation
11.1 Global Emphysema Market by Diagnosis
11.1.1 Market Overview
11.1.2 Imaging Test
11.1.3 Lab Test
11.1.4 Spirometry
11.1.5 Others
11.2 Global Emphysema Market by Type
11.2.1 Market Overview
11.2.2 Centriacinar
11.2.3 Panacinar
11.2.4 Paraseptal
11.2.5 Others
11.3 Global Emphysema Market by Treatment Type
11.3.1 Market Overview
11.3.2 Medication
11.3.2.1 Bronchodilators
11.3.2.2 Steroids
11.3.2.3 Others
11.3.3 Surgery
11.3.4 Others
11.4 Global Emphysema Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Parenteral
11.4.4 Others
11.5 Global Emphysema Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Emphysema Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Homecare
11.6.4 Specialty Centres
11.6.5 Others
11.7 Global Emphysema Market by Distribution Channel
11.7.1 Market Overview
11.7.2 Hospital Pharmacy
11.7.3 Online Pharmacy
11.7.4 Retail Pharmacy
11.8 Global Emphysema Market by Region
11.8.1 Market Overview
11.8.2 North America
11.8.3 Europe
11.8.4 Asia Pacific
11.8.5 Latin America
11.8.6 Middle East and Africa
12 North America Emphysema Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Emphysema Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Emphysema Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Emphysema Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Emphysema Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Mylan N.V.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Fresenius Kabi AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Hikma Pharmaceuticals PLC
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Novartis AG
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 F. Hoffmann-La Roche Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bristol Myers Squibb Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GSK Plc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Bayer AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Sun Pharmaceutical Industries Ltd.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Intersect ENT, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolioa
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Global Emphysema Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global emphysema treatment market reached a value of USD 4.4 billion in 2022.
The market is projected to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to reach a value of USD 7.3 billion by 2031.
The major drivers of the industry, such as the rising pollution levels, increasing smoking population, developing healthcare facilities, increasing prevalence of chronic obstructive pulmonary diseases, and escalating disposable incomes, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the growing investments in R&D activities and the advancing medical sector.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading treatment types in the market are smoking cessation, bronchodilators, steroids, leukotriene modifiers, supplemental oxygen, antibiotics, gene therapy, and surgery transplant, among others.
The major types of diseases considered in the market are shortness of breath, chronic cough, chronic mucus production, chest tightness, wheezing, fatigue, lowered immunity, weight loss, and thin and very pink skin, among others.
The significant end use sectors in the industry are hospital, clinics, and surgical centre, among others.
The major players in the industry are Pulmonx Corporation, Kamada Limited, Pfizer Inc., and Uptake Medical Technology Inc., among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.